Funded by Innovation and Technology Commission (ITC) of the Hong Kong Government, Centre for Chinese Herbal Medicine Drug Development Limited (the Centre) was established in September 2020 to accelerate the development of Chinese Herbal Medicine (CHM)-based drugs, and serve as a strategic platform to promote collaborations among local and international researchers, institutions and industry. The Centre aims to achieve the goal by enhancing the quality of pre-clinical and clinical CHM research and transforming the results into pharmaceutical products for international markets. In particular, the Centre develops treatments and cures for diseases such as ulcerative colitis and chronic constipation. It also supports the incubation of new CHM-based pharmaceutical start-ups that will target the global market, and nurtures talent for CHM research in Hong Kong.
Translating traditional Chinese medicine wisdom into pharmaceutical products with the best global partners using international standards.
- ● To develop a CHM drug development platform. Each component of the platform could either work together as the pipeline for CHM-based new drug development or work separately for a specific CHM formula related preclinical or clinical studies.
- ● To develop CHM-based new pharmaceutical drugs based on the requirements of the NMPA in China, the Chinese Medicine Council of Hong Kong and the US FDA, targeting the market needs, with the CHM formulas that are supported by evidence-based pre-clinical and clinical researches.
- ● To nurture talents for CHM research in Hong Kong.